Kiadis Pharma launch­es a pri­vate place­ment of approx­i­mate­ly 2.6 mil­lion new shares

Amsterdam, The Netherlands, March 12, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing a T-cell immunother­a­py prod­uct designed to reduce Graft ver­sus Host Disease (GVHD) in hematopoi­et­ic stem cell trans­plan­ta­tions (HSCT) today announces the launch of a pri­vate place­ment of approx­i­mate­ly 2.6 mil­lion new shares to insti­tu­tion­al investors, rep­re­sent­ing approx­i­mate­ly 14.8% of the Company’s cur­rent issued cap­i­tal (the “Placing”). Existing share­hold­ers of the Company will not have pre-emp­tive rights in rela­tion to the new shares to be issued. The new shares will rank pari pas­su in all respects with the cur­rent­ly out­stand­ing shares of the Company. With the cap­i­tal increase, the Company intends to make full use of the remain­ing author­i­ty that the share­hold­ers
meet­ing has grant­ed to the Company’s Management and Supervisory Boards to issue new shares.

Kiadis Pharma intends to use the net pro­ceeds of the Placing to:
– con­tin­ue the Phase 3 inter­na­tion­al, ran­dom­ized, con­trolled, mul­ti­cen­tre clin­i­cal tri­al for ATIR101 in the United States, Canada and Europe;
gen­er­ate addi­tion­al man­u­fac­tur­ing capac­i­ty at ven­dors and to refur­bish, equip and staff its leased man­u­fac­tur­ing facil­i­ty;
– fur­ther pre­pare the Company for com­mer­cial­iza­tion by invest­ing into a com­mer­cial orga­ni­za­tion, mar­ket access prepa­ra­tion and reim­burse­ment dis­cus­sions;
– sup­port fur­ther pro­duc­tion process opti­miza­tion of ATIR;
– expand the orga­ni­za­tion to accom­mo­date the increased num­ber of activ­i­ties;
– start a fur­ther clin­i­cal tri­al to assess the ben­e­fit of ATIR101 in con­junc­tion with
anoth­er T-cell deplet­ed hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT) pro­to­col or with a cyclophos­phamide-based hap­lo trans­plan­ta­tion pro­to­col;
– apply funds for debt repay­ment, cap­i­tal expen­di­tures, gen­er­al and admin­is­tra­tive expens­es, gen­er­al cor­po­rate pur­pos­es in line with Kiadis Pharma’s strat­e­gy and oth­er work­ing cap­i­tal needs; and
– finance poten­tial oppor­tu­ni­ties to broad­en and diver­si­fy the research and devel­op­ment port­fo­lio (e.g. through in-licens­ing or acquir­ing pro­grams and com­pa­nies with syn­er­gis­tic or com­ple­men­tary tech­nolo­gies, prod­ucts and/or prod­uct can­di­dates).

The new shares will be placed with insti­tu­tion­al investors through an accel­er­at­ed book­build­ing process and the sub­scrip­tion price and the num­ber of shares to be issued in the Placing will be deter­mined through this process. The book­build­ing peri­od for the Placing will com­mence today with imme­di­ate effect and will close at short notice. In rela­tion to the Placing, the Company has, sub­ject to cus­tom­ary exemp­tions, agreed to a lock-up under­tak­ing for a peri­od of 90 cal­en­dar days after the set­tle­ment date on future share issuances. In addi­tion, and also sub­ject to cus­tom­ary exemp­tions, the two largest share­hold­ers of the Company (funds rep­re­sent­ed by and/or affil­i­at­ed with Life Sciences Partners and Draper Esprit, togeth­er rep­re­sent­ing 43.8% of the share cap­i­tal of the Company) as well as all mem­bers of the Company’s Management Board and Supervisory Board have agreed to a lock-up under­tak­ing for a peri­od of 90 cal­en­dar days after the set­tle­ment date on future share dis­pos­als.

The Company will announce the num­ber of new shares placed and the sub­scrip­tion price in the Placing in a sub­se­quent press release expect­ed to be pub­lished before the begin­ning of trad­ing on Euronext Amsterdam and Euronext Brussels on Tuesday March 1.

A reg­is­tra­tion doc­u­ment, approved by the Netherlands Authority for the Financial Markets (AFM) on March 12, 2018, is avail­able free of charge on the Company’s web­site ( A sum­ma­ry and secu­ri­ties note, which togeth­er with the reg­is­tra­tion doc­u­ment will form the list­ing prospec­tus on the basis of which the new shares will be admit­ted to trad­ing on Euronext Amsterdam and Euronext Brussels, will be sub­mit­ted to the AFM with a view to receiv­ing its approval on or about March 13, 2018, fol­low­ing which it will be made avail­able free of charge on the Company’s web­site (

Jefferies International Limited is act­ing as Sole Bookrunner, Canaccord Genuity Limited as Lead Manager, Chardan as Co-Lead Manager and LifeSci Capital LLC as Co-Manager in con­nec­tion with the Placing. Saola Healthcare Partners is act­ing as finan­cial advi­sor to the Company.

Leave a Reply

Your email address will not be published. Required fields are marked *